These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 37848

  • 1. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
    Schneider E, Fischer PA, Jacobi P, Reh W.
    Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848
    [Abstract] [Full Text] [Related]

  • 2. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M, Barbeau A.
    Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
    [Abstract] [Full Text] [Related]

  • 3. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
    Carolei A, Meco G, Casacchia M, Agnoli A.
    Acta Neurol (Napoli); 1976 Feb; 31(4):475-8. PubMed ID: 16441
    [No Abstract] [Full Text] [Related]

  • 4. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B, Verhey FR, Adam JJ, Weber W, Leentjens AF.
    Clin Neuropharmacol; 2006 Feb; 29(5):276-85. PubMed ID: 16960473
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
    Bergemann N, Baas H, Fischer PA.
    Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study.
    Laitinen LV, Vilkki J.
    Ann Clin Res; 1971 Aug; 3(4):207-11. PubMed ID: 4937341
    [No Abstract] [Full Text] [Related]

  • 10. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
    Caraceni T, Parati EA, Girotti F, Celano I, Frigerio C, Cocchi D, Müller EE.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):217-22. PubMed ID: 39308
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG, Carter JH, Carlson NE.
    Arch Neurol; 2007 Mar 21; 64(3):319-23. PubMed ID: 17353373
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of ciladopa on Parkinson's disease: a preliminary report.
    Weiner WJ, Berger JR.
    Adv Neurol; 1987 Mar 21; 45():583-6. PubMed ID: 3548268
    [No Abstract] [Full Text] [Related]

  • 18. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
    Kastin AJ, Schally AV, Kostrzewa RM.
    Fed Proc; 1980 Sep 21; 39(11):2931-6. PubMed ID: 6105977
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia.
    Ehrensing RH, Kastin AJ, Larsons PF, Bishop GA.
    Dis Nerv Syst; 1977 Apr 21; 38(4):303-7. PubMed ID: 14814
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.